AlprenoximeAlternative Names: CDDD 1815; HGP 5
Latest Information Update: 07 Oct 1996
At a glance
- Originator Unknown
- Developer Pharmos Corporation
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 07 Oct 1996 Discontinued-II for Glaucoma in USA (Ophthalmic)
- 15 Jul 1994 Phase-II clinical trials for Glaucoma in USA (Ophthalmic)